Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Society to Request 3-month Prescription Periods for Anti-HIV Drugs
February 19, 2001
- Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
- RA Patient Group Holds Survey on Clinical Trials
February 19, 2001
- Long, Short-term Goals Must Be Set for Reform: JMA President
February 19, 2001
- Asthma Telemedicine Should Reduce Asthma Deaths: Teijin Seminar
February 19, 2001
- Chugai's '75-year History' Published
February 19, 2001
- Standard Drug Name, Lab Test Masters Completed
February 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
- Locate in Scotland, Scottish Trade International Move to New Office
February 19, 2001
- Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
- Korosho Denies Need for Further Deregulation
February 19, 2001
- Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
- FPMAJ Drafts GL for Distinctive Labeling of Paper, Plastic Packages
February 19, 2001
- J&J Pushes Sales of Tylenol Series
February 19, 2001
- Fujisawa Aims at Top Share in Market for Psychotropics
February 19, 2001
- Guide to Prepare NDA Dossiers According to CTD Published
February 19, 2001
- Rohto to Introduce Sliming Supplement from Italy
February 19, 2001
- Santen Licenses in Anti-APO-1 Antibody from Centocor
February 19, 2001
- REGULATORY NEWS IN BRIEF -1-
February 19, 2001
- DyDo to Aggressively Expand Drugstore Business
February 19, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…